Leerink Partnrs Weighs in on CLOV Q2 Earnings

Clover Health Investments, Corp. (NASDAQ:CLOV - Free Report) - Research analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of Clover Health Investments in a report released on Wednesday, May 7th. Leerink Partnrs analyst W. Mayo expects that the company will post earnings of $0.03 per share for the quarter. The consensus estimate for Clover Health Investments' current full-year earnings is ($0.12) per share. Leerink Partnrs also issued estimates for Clover Health Investments' Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.00 EPS, FY2025 earnings at $0.11 EPS, Q1 2026 earnings at $0.05 EPS, Q3 2026 earnings at $0.06 EPS, Q4 2026 earnings at $0.00 EPS, FY2026 earnings at $0.18 EPS, FY2027 earnings at $0.24 EPS, FY2028 earnings at $0.28 EPS and FY2029 earnings at $0.32 EPS.

Clover Health Investments (NASDAQ:CLOV - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.12. The business had revenue of $462.33 million for the quarter, compared to analysts' expectations of $466.93 million. Clover Health Investments had a negative return on equity of 25.46% and a negative net margin of 5.92%.

Separately, Canaccord Genuity Group upped their price objective on Clover Health Investments from $4.20 to $4.50 and gave the company a "buy" rating in a report on Monday, March 3rd.

Clover Health Investments Price Performance

Shares of NASDAQ CLOV traded down $0.07 during midday trading on Monday, reaching $3.40. 8,719,216 shares of the company traded hands, compared to its average volume of 6,771,842. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -17.00 and a beta of 1.99. The stock has a 50-day moving average price of $3.56 and a 200 day moving average price of $3.71. Clover Health Investments has a 52 week low of $0.86 and a 52 week high of $4.87.

Institutional Trading of Clover Health Investments

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Graypoint LLC acquired a new stake in Clover Health Investments during the 4th quarter worth $632,000. JPMorgan Chase & Co. bought a new position in shares of Clover Health Investments in the 3rd quarter worth $448,000. Barclays PLC acquired a new stake in shares of Clover Health Investments during the third quarter worth $298,000. Swiss National Bank increased its holdings in Clover Health Investments by 6.3% in the fourth quarter. Swiss National Bank now owns 802,100 shares of the company's stock valued at $2,527,000 after purchasing an additional 47,700 shares during the last quarter. Finally, Counterpoint Mutual Funds LLC increased its holdings in Clover Health Investments by 153.0% in the fourth quarter. Counterpoint Mutual Funds LLC now owns 233,392 shares of the company's stock valued at $735,000 after purchasing an additional 141,148 shares during the last quarter. 19.77% of the stock is owned by institutional investors.

Insider Activity at Clover Health Investments

In other news, Director Carladenise Armbrister Edwards sold 200,000 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $3.61, for a total transaction of $722,000.00. Following the completion of the sale, the director now owns 273,227 shares of the company's stock, valued at approximately $986,349.47. This trade represents a 42.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Brady Patrick Priest sold 75,000 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $3.68, for a total transaction of $276,000.00. Following the sale, the chief executive officer now directly owns 2,418,151 shares in the company, valued at $8,898,795.68. This trade represents a 3.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 327,500 shares of company stock valued at $1,197,500. 22.28% of the stock is currently owned by corporate insiders.

Clover Health Investments Company Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.